Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

NCT06114407 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

184

Enrollment

OTHER

Sponsor class

Conditions

Spondyloarthritis, Axial

Interventions

DRUG: Baricitinib 2mg
DRUG: Tofacitinib 5 mg

Sponsor

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Collaborators

[object Object]